UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Annals of oncology, 2020-07, Vol.31 (7), p.942-950

2020

Volltextzugriff (PDF)

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Annals of oncology, 2023-03, Vol.34 (3), p.262-274

2023

Volltextzugriff (PDF)

Industry corner: perspectives and controversies - The challenges of patient access to new medicines

Annals of oncology, 2017-03, Vol.28 (3), p.658-663

2017

Volltextzugriff (PDF)

Lutte antiérosive : Réhabilitation des sols tropicaux et protection contre les pluies exceptionnelles

2012

Volltextzugriff (PDF)

Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study

Annals of oncology, 2017-09, Vol.28, p.v494

2017

Volltextzugriff (PDF)

Electrochemotherapy: a new treatment of solid tumors

Journal of experimental & clinical cancer research, 2003-12, Vol.22 (4 Suppl), p.145-148

2003

Volltextzugriff (PDF)

PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma: Topic: Medical Oncology

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1577-S1577

2017

Volltextzugriff (PDF)

PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1577

2017

Volltextzugriff (PDF)

LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)

Annals of oncology, 2017-04, Vol.28, p.ii58

2017

Volltextzugriff (PDF)

A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS)

Annals of oncology, 2017-04, Vol.28, p.ii49

2017

Volltextzugriff (PDF)

P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2021-S2022

2017

Volltextzugriff (PDF)

Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)

Annals of oncology, 2017-09, Vol.28, p.v569-v570

2017

Volltextzugriff (PDF)

Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study

Japanese journal of clinical oncology, 2011-05, Vol.41 (5), p.718-722

2011

Volltextzugriff (PDF)

OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1555

2017

Volltextzugriff (PDF)

OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1555-S1555

2017

Volltextzugriff (PDF)

Phase I Dose-Escalation Study to Determine the Maximum Tolerated Dose (Mtd) of Nintedanib (Bibf 1120) in Combination with Carboplatin/Pegylated Liposomal Doxorubicin (Pld) in Patients (Pts) with Recurrent Ovarian Cancer (Roc)

Annals of oncology, 2014-09, Vol.25, p.iv310

2014

Volltextzugriff (PDF)

889PPHASE I DOSE-ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF NINTEDANIB (BIBF 1120) IN COMBINATION WITH CARBOPLATIN/PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (ROC)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv310-iv311

2014

Volltextzugriff (PDF)

Une errance diagnostique pour un site singulier de pyoderma gangrenusum

Revue du rhumatisme (Ed. française : 1993), 2006-11, Vol.73 (10), p.1219-1219

2006

Volltextzugriff (PDF)

446PD - Phase I Study of Afatinib (BIBW 2992), An Erbb Family Blocker Plus Nintedanib (BIBF 1120), A Triple Angiokinase Inhibitor, in Patients (PTS) With Advanced Solid Tumours

Annals of oncology, 2012-09, Vol.23, p.ix155-ix155

2012

Volltextzugriff (PDF)

Phase I Study of Afatinib (BIBW 2992), An Erbb Family Blocker Plus Nintedanib (BIBF 1120), A Triple Angiokinase Inhibitor, in Patients (PTS) With Advanced Solid Tumours

Annals of oncology, 2012-09, Vol.23, p.ix155

2012

Volltextzugriff (PDF)

L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13153-e13153

2010

Volltextzugriff (PDF)

Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2 nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5028-5028

2008

Volltextzugriff (PDF)

Successful repetitive treatments by electrochemotherapy of multiple unresectable Kaposi sarcoma nodules

European journal of cancer (1990), 2006

2006

Volltextzugriff (PDF)

Interactions between Helcococcus kunzii and Staphylococcus aureus: How a commensal bacterium modulates the virulence and metabolism of a pathogen in a chronic wound in vitro model

BMC microbiology, 2024-10, Vol.24 (1), p.406-13, Article 406

2024

Volltextzugriff (PDF)

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

The New England journal of medicine, 2019-02, Vol.380 (6), p.539-548

2019

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(102)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Physics
(20)
Materials Science
(18)
Physical Sciences
(17)
Technology
(16)
Humans
(13)
Life Sciences & Biomedicine
(12)
Materials Science, Multidisciplinary
(12)
Physics, Applied
(12)
Oncology
(9)
Condensed Matter
(8)
Exact Sciences And Technology
(7)
Photovoltaic Cells
(7)
Physics, Condensed Matter
(7)
Deposition
(6)
Middle Aged
(6)
Thin Films
(6)
Aged
(5)
Female
(5)
Sciences Exactes Et Technologie
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Industry corner: perspectives and controversies - The challenges of patient access to new medicines

Lutte antiérosive : Réhabilitation des sols tropicaux et protection contre les pluies exceptionnelles

Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study

Electrochemotherapy: a new treatment of solid tumors

PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma: Topic: Medical Oncology

PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma

LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)

A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS)

P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma

Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)

Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study

OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma

OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology

Phase I Dose-Escalation Study to Determine the Maximum Tolerated Dose (Mtd) of Nintedanib (Bibf 1120) in Combination with Carboplatin/Pegylated Liposomal Doxorubicin (Pld) in Patients (Pts) with Recurrent Ovarian Cancer (Roc)

889PPHASE I DOSE-ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF NINTEDANIB (BIBF 1120) IN COMBINATION WITH CARBOPLATIN/PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (ROC)

Une errance diagnostique pour un site singulier de pyoderma gangrenusum

446PD - Phase I Study of Afatinib (BIBW 2992), An Erbb Family Blocker Plus Nintedanib (BIBF 1120), A Triple Angiokinase Inhibitor, in Patients (PTS) With Advanced Solid Tumours

Phase I Study of Afatinib (BIBW 2992), An Erbb Family Blocker Plus Nintedanib (BIBF 1120), A Triple Angiokinase Inhibitor, in Patients (PTS) With Advanced Solid Tumours

L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study

Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2 nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU)

Successful repetitive treatments by electrochemotherapy of multiple unresectable Kaposi sarcoma nodules

Interactions between Helcococcus kunzii and Staphylococcus aureus: How a commensal bacterium modulates the virulence and metabolism of a pathogen in a chronic wound in vitro model

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

Suchergebnisse filtern